Bank of America Corporation vs Bristol-Myers Squibb Company: Strategic Comparison

This in-depth comparison examines Bank of America Corporation and Bristol-Myers Squibb Company across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Bank of America Corporation on its own, evaluating Bristol-Myers Squibb Company, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Bank of America Corporation and Bristol-Myers Squibb Company is widest.

On the headline numbers, Bank of America Corporation reports annual revenue of $113.1B against $48.2B for Bristol-Myers Squibb Company, while their respective market capitalizations stand at $380.6B and $127.5B. Both Bank of America Corporation and Bristol-Myers Squibb Company are headquartered in United States, so they compete in a shared home market and regulatory environment.

Bank of America Corporation: Bank of America is a universal bank with $3.41T of assets at December 31, 2025, the second largest in the United States by that measure. It runs two businesses that look nothing alike. For roughly 69 million consumer and small business clients it is a retail bank: the branch on the corner, the checking account, the card and the mortgage. For companies, governments and institutional investors it is an investment bank and trading house operating as BofA Securities, with Merrill and the Private Bank managing $4.75T of client balances. Consumer Banking produced $43.7B of revenue in 2025, Global Wealth and Investment Management $24.9B, Global Banking $24.1B and Global Markets $24.1B.

Bristol-Myers Squibb Company: Bristol Myers Squibb (BMS) is a U.S. biopharmaceutical company headquartered in Princeton, New Jersey, and listed on the New York Stock Exchange as BMY. It develops and sells prescription medicines for cancer, blood disorders, immune diseases, heart disease and schizophrenia. Its best-known products are Eliquis, the anticoagulant it sells with Pfizer, and Opdivo, a PD-1 checkpoint inhibitor. With $48.2 billion of 2025 revenue and a market value of about $127 billion at the end of September 2026, it is one of the largest U.S. drugmakers by sales.

Bank of America Corporation and Bristol-Myers Squibb Company pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Bank of America Corporation and Bristol-Myers Squibb Company.

Bank of America Corporation business model: The model is a deposit-funded spread business layered with fee income. Consumer Banking gathers low-cost deposits and lends through mortgages, cards and auto loans, producing $43.7B of revenue in 2025 and $12.2B of net income. Global Wealth and Investment Management charges fees on $4.75T of client balances, including $2.18T of assets under management, for $24.9B of revenue. Global Banking lends to companies and sells treasury solutions, underwriting and advice, for $24.1B. Global Markets makes markets in rates, credit, currencies, commodities and equities, for $24.1B. Across the company, net interest income was $60.1B in 2025 and fees and commissions $39.4B, of which investment and brokerage services were $20.0B and investment banking fees $6.6B.

Bristol-Myers Squibb Company business model: BMS discovers, licenses or buys drug candidates, takes them through clinical trials, and sells approved medicines under patent protection to wholesalers, specialty pharmacies and hospitals. Net product sales were $46.8 billion of the $48.2 billion total in 2025; alliance, royalty and other revenues made up the remaining $1.4 billion, including royalties from Merck on Winrevair. Eliquis is developed and sold with Pfizer, which shares its costs and profits. About 69 percent of 2025 revenue came from the United States, so U.S. pricing policy matters more to BMS than to most European rivals. Because every patent runs out, the model depends on replacing revenue: BMS paid $74 billion for Celgene in 2019, $13.1 billion for MyoKardia in 2020 and about $23 billion for Karuna, Mirati and RayzeBio in early 2024.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Bank of America Corporation stack up against those of Bristol-Myers Squibb Company.

Bank of America Corporation competitive advantage: Bank of America's advantage is cheap, sticky funding. It held $2.02T of deposits at December 31, 2025, much of it in transaction accounts, and the total deposit spread was 2.92 percent in 2025 against 2.77 percent in 2024. Scale compounds it: approximately 69 million consumer and small business clients, 3,628 financial centers across 38 states and the District of Columbia, about 15,000 ATMs, and digital platforms with 49 million active users including 41 million on mobile. Preferred Rewards ties card rewards, lending discounts and fee waivers to combined bank and Merrill balances, so consolidating assets pays more than moving them. Erica, the assistant launched in 2018, has handled more than 3.2 billion client interactions and keeps routine servicing inside the app.

Bristol-Myers Squibb Company competitive advantage: BMS's advantage is its expertise in oncology and its large commercial and regulatory organization. Developing a cancer immunotherapy is complex, and winning approval from regulators and getting doctors to prescribe it requires an established global sales and regulatory team. Smaller biotech companies often lack that infrastructure, so they partner with or sell to a company like BMS to bring their discoveries to market.

Future prospects matter as much as current results. The growth strategies below explain how Bank of America Corporation and Bristol-Myers Squibb Company each plan to expand from here.

Bank of America Corporation growth strategy: Growth comes from deepening existing relationships rather than buying banks. Consumer Banking adds clients through digital channels, with 49 million active digital users and 41 million mobile users at the end of 2025, while the branch network is consolidated slowly, down 72 to 3,628 centers during the year, and rebuilt in selected metropolitan markets. Wealth management is the main fee engine: client balances rose 12 percent to $4.75T and assets under management reached $2.18T in 2025. Global Banking pairs commercial bankers with investment bankers to win mid-market mandates, and CashPro serves treasury clients in more than 145 jurisdictions. Preferred Rewards ties pricing to combined banking and Merrill balances so assets stay inside the company.

Bristol-Myers Squibb Company growth strategy: BMS is pursuing growth on three fronts. First, scaling the Growth Portfolio (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag, Cobenfy and others), which rose 17 percent to $26.4 billion in 2025 and 15 percent to $7.56 billion in the second quarter of 2026. Second, buying and licensing late-stage science: Mirati ($4.8 billion plus a contingent value right of up to $1 billion), RayzeBio ($4.1 billion) and Karuna ($14 billion) closed in early 2024; a June 2025 deal with BioNTech for the bispecific BNT327 carried $1.5 billion upfront and up to $11.1 billion in total; and Orbital Therapeutics was bought for $1.5 billion in October 2025 for in vivo CAR-T in autoimmune disease. Third, cost cuts: a $1.5 billion savings program announced in 2024 was extended in 2025 with a further $2 billion targeted by the end of 2027.

A closer look at the financial trajectory of Bank of America Corporation and Bristol-Myers Squibb Company rounds out the comparison.

Bank of America Corporation: Bank of America earns in two streams. Net interest income was $60.1B in 2025 and noninterest income $53.0B, for total revenue net of interest expense of $113.1B and net income of $30.5B, or $3.81 per diluted share. Deposits of $2.02T funded $1.19T of loans and leases plus a $927.4B debt securities portfolio. Fees carried the year: investment and brokerage services rose $2.2B to $20.0B, investment banking fees rose to $6.6B, and market making fell $953M to $12.0B. Credit stayed contained, with the total consumer net charge-off ratio at 0.88 percent and the card ratio at 3.68 percent. The efficiency ratio improved to 61.65 percent from 63.12 percent, and common equity tier 1 capital was $201.4B, an 11.4 percent standardized ratio against a 10.0 percent minimum.

Bristol-Myers Squibb Company: Revenue grew from $19.4 billion in 2016 to $42.5 billion in 2020 as Celgene's sales were added, and has stayed between $45.0 billion and $48.3 billion since 2021. Net earnings are far less stable because BMS expenses acquired in-process R&D: the $11.4 billion MyoKardia charge produced a $9.0 billion net loss in 2020, and the Karuna charge produced an $8.9 billion loss in 2024. Cash generation is steadier, with free cash flow of about $12.8 billion in 2025. That cash funds a dividend raised for a 17th straight year in February 2026, to $0.63 a quarter, and debt reduction, from $51.2 billion at the end of 2024 to $47.2 billion a year later. On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion, from $46.0 to $47.5 billion, after second-quarter revenue rose 6 percent to $12.97 billion.